Mariner’s Acurx Pharmaceuticals ACXP Stock Holding History

Mariner’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-800	Closed	-$48K	–	2739
2022 Q3	$48K	Buy	+800	New	+$59.9K	﹤0.01%	2312

Other funds holding ACXP

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DAM

Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

SFA

Semmax Financial Advisors Winston Salem, North Carolina $388M AUM 14.23% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Mariner's ACXP Position: Q4 2022 in Review

Mariner sold out of Acurx Pharmaceuticals (ACXP) in Q4 2022, closing a stake of 800 shares — an estimated $48K sold.

Mariner first reported a position in ACXP in Q3 2022 and held it in 1 quarter. The position peaked at $48K in Q3 2022. 14 funds tracked by Wall St. Rank hold ACXP as of Q4 2022.

Mariner reported no remaining Acurx Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Mariner sold 800 Acurx Pharmaceuticals shares in Q4 2022, an estimated $48K.
Mariner first reported a position in Acurx Pharmaceuticals in Q3 2022 and held it in 1 quarter.
Mariner's Acurx Pharmaceuticals position peaked at $48K in Q3 2022.
14 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q4 2022.

Based on Mariner's 13F filing for Q4 2022, filed 14 Feb 2023.